Antisense oligonucleotide inhibition of serine/threonine kinases: An innovative approach to cancer treatment

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 437-449

  Cho Chung, Yoon S ^a  

^a Lab of Tumor Immunology and Biology   (United States)

Author keywords

Antisense oligonucleotide; cAMP dependent protein kinase; Cancer cells; Growth inhibition; MAP kinase; Protein kinase C

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GROWTH FACTOR; HORMONE; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTRANSMITTER; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; CANCER; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 0033025959     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00043-6     Document Type: Conference Paper

References (97)

1. Altmann K.-H., Dean N.M., Fabbro D., Freier S.M., Geiger T., Haner R., Huskin D., Martin P., Monia B.P., Muller M., Natt F., Nicklin P.N., Phillips J., Pieles V., Sasmor H., Moser H. Second generation of antisense oligonucleotides. from nuclease resistance to biological efficacy in animals Chimia. 50:1996;168-176.
2. Asaoka Y., Nakamura S., Yoshida K., Nishizuka Y. Protein kinase C, calcium and phospholipid degradation. Trends Biochem. Sci. 17:1992;414-417.
3. Bacon T.A., Wickstrom E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides. maximum efficacy at the 5′ cap region Oncogene Res. 6:1991;13-19.
4. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol. Ther. 59:1993;257-280.
5. Beebe S.J., Corbin J.D. Cyclic nucleotide-dependent protein kinases. Boyer P.D., Krebs E.G. The Enzymes. Control by Phosphorylation, Part A, Vol. 17:1986;43-111 Academic Press, New York.
6. Beebe S.J., Oyen O., Sandberg M., Froysa A., Hansson V., Jahnsen T. Molecular cloning of a unique tissue-specific protein kinase (Cgamma) from human testis - representing a third isoform for the catalytic subunit of the cAMP-dependent protein kinase. Mol. Endocrinol. 4:1990;465-475.
7. Bennett C.F., Dean N., Ecker D.J., Monia B.P. Pharmacology of antisense therapeutic agents. cancer and inflammation Agrawal S. Methods in Molecular Medicine. Antisense Therapeutics:1995;13-46 Humana Press, Totowa.
8. Borner C., Eppenberger U., Wyss R., Fabbro D. Continuous synthesis of two protein kinase-C-related proteins after down-regulation by phorbol esters. Proc. Natl. Acad. Sci. USA. 85:1988;2110-2114.
9. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:1988;255-271.
10. Bos J.L. ras oncogenes in human cancer. a review Cancer Res. 49:1989;4682-4689.
11. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
12. Bradbury A.W., Carter D.C., Miller W.R., Cho-Chung Y.S., Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br. J. Cancer. 69:1994;738-742.
13. Chiang M.Y., Chan H., Zounes M.A., Freier S.M., Lima W.F., Bennett C.F. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:1991;18162-18171.
14. Cho-Chung Y.S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy. new approaches to therapy. Perspectives in cancer research Cancer Res. 50:1990;7093-7100.
15. 2′-dibutyryl cyclic adenosine 3′:5′-monophosphate on 7,12-dimethylbenz[a]anthracene mammary tumor induction in the rat and its relationship to cyclic adenosine 3′:5′-monophosphate metabolism and protein kinase. Cancer Res. 43:1983;2736-2740.
16. Cho-Chung Y.S., Nesterova M., Agrawal S., Noguchi K. Protein kinase A-directed antisense restrains tumor growth. use of phosphorothioate oligonucleotides containing segments of either 2′-O-methyl-oligoribonucleotide or methylphosphonate oligonucleotide Proc. Am. Assoc. Cancer Res. 37:1996;351.
17. Cho-Chung Y.S., Nesterova M., Kondrashin A., Noguchi K., Srivastava R., Pepe S. Antisense-protein kinase A. a single-gene-based therapeutic approach Antisense Nucleic Acid Drug Dev. 7:1997;217-223.
18. Ciardiello F., Tortora G., Kim N., Clair T., Ally S., Salomon D.S., Cho-Chung Y.S. 8-Chloro-cAMP inhibits transforming growth factor α transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. J. Biol. Chem. 265:1990;1016-1020.
19. Ciardiello F., Pepe S., Bianco C., Baldassarre G., Ruggiero A., Bianco C., Selvam M.P., Bianco A.R., Tortora G. Down-regulation of RIα subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erb B-2 proto-oncogenes. Int. J. Cancer. 53:1993;438-443.
20. Crooke S.T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:1992;329-376.
21. Crooke S.T. Therapeutic Applications of Oligonucleotides. 1995;R. G. Landes Company, Austin.
22. Daum G., Eisenmann-Tappe I., Fries H.-W., Troppmair J., Rapp U.R. The ins and outs of Raf kinases. Trends Biochem. Sci. 19:1994;474-480.
23. Dean N.M., McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91:1994;11762-11766.
24. Dean N.M., McKay R., Condon T.P., Bennett C.F. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:1994;16416-16424.
25. Dean N.M., McKay R., Miraglia L., Howard R., Cooper S., Giddings J., Nicklin P., Meister L., Zeil R., Geiger T., Muller M., Fabbro D. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-alpha expression. Cancer Res. 56:1996;3499-3507.
26. Dean N.M., Lemonidis K., McKay R., Miraglia L., Trent K., Pribble J.P. The use of antisense oligonucleotides to inhibit expression of isozymes of protein kinase C. Stein C.A., Krieg A.M. In. Applied Antisense Oligonucleotide Technology:1998;193-205 Wiley-Liss, New York.
27. Dekker L.V., Parker P.J. Protein kinase C - a question of specificity. Trends Biochem. Sci. 19:1994;73-77.
28. Dolnick B.J. Antisense agents in cancer research and therapeutics. Cancer Invest. 9:1991;185-194.
29. Fossberg T.M., Døskeland S.O., Ueland P.M. Protein kinases in human renal cell carcinoma and renal cortex. A comparison of isozyme distribution and of responsiveness to adenosine 3′:5′-cyclic monophosphate. Arch. Biochem. Biophys. 189:1978;272-281.
30. Freier S.M., Tinoco I. Jr. The binding of complementary oligoribonucleotides to yeast initiator transfer RNA. Biochemistry. 14:1975;3310-3314.
31. Fukui M., Yamamoto T., Kawai S., Maruo K., Toyoshima K. Detection of a raf-related and two other transforming DNA sequences in human tumors maintained in nude mice. Proc. Natl. Acad. Sci. USA. 82:1985;5954-5958.
32. Gharrett A.J., Malkinson A.M., Sheppard J.R. Cyclic AMP-dependent protein kinases from normal and SV40-transformed 3T3 cells. Nature. 264:1976;673-675.
33. Gong J., Traganos F., Darzynkiewicz Z. Expression of cyclins B and E in individual MOLT-4 cells and in stimulated human lymphocytes during their progression through the cell cycle. Int. J. Oncol. 3:1993;1037-1042.
34. Handschin J.C., Eppenberger U. Altered cellular ratio of type I and type II cyclic AMP-dependent protein kinase in human mammary tumors. FEBS Lett. 106:1979;301-304.
35. Herschlag D., Cech T.R. Catalysis of RNA cleavage by the Tetrahymena thermophila ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. Biochemistry. 29:1990;10172-10180.
36. Heywood S.M. tcRNA as a naturally occurring antisense RNA in eukaryotes. Nucleic Acids Res. 14:1986;6771-6772.
37. Ho S.P., Britton D.H., Stone B.A., Behrens D.L., Leffet L.M., Hobbs F.W., Miller J.A., Trainor G.L. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 24:1996;1901-1907.
38. Iversen P. In vivo studies with phosphorothioate oligonucleotides. pharmacokinetics prologue Anticancer Drug Des. 6:1991;531-538.
39. Krebs E.G., Beavo J.A. Phosphorylation-dephosphorylation of enzymes. Annu. Rev. Biochem. 48:1979;923-959.
40. Ledinko N., Chan I.-J. Increase in type I cyclic adenosine 3′:5′-monophosphate-dependent protein kinase activity and specific accumulation of type I regulatory subunits in adenovirus type 12-transformed cells. Cancer Res. 44:1984;2622-2627.
41. Lee J.-S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Foto A.T., Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:1994;627-638.
42. Lee Y.S., Dlugosz A.A., McKay R., Dean N.M., Yuspa S.H. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes. Mol. Carcinog. 18:1997;44-53.
43. Levy F.O., Oyen O., Sandberg M., Tasken K., Eskild W., Hansson V., Jahnsen T. Molecular cloning, complementary deoxyribonucleic acid structure and predicted full-length amino acid sequence of the hormone-inducible regulatory subunit of 3′:5′-cyclic adenosine monophosphate-dependent protein kinase from human testis. Mol. Endocrinol. 2:1988;1364-1373.
44. Lima W., Monia B.P., Ecker D.J., Freier S.M. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry. 31:1992;12055-12061.
45. Livesey S.A., Kemp B.E., Re C.A., Partridge N.C., Martin T.J. Selective hormonal activation of cyclic AMP-dependent protein kinase isoenzymes in normal and malignant osteoblasts. J. Biol. Chem. 257:1982;14983-14987.
46. Lohmann S.M., Walter U. Regulation of the cellular and subcellular concentrations and distribution of cyclic nucleotide-dependent protein kinases. Greengard P., Robison G.A. Advances in Cyclic Nucleotide and Protein Phosphorylation Research, Vol. 18. 1984;63-117 Raven Press, New York.
47. McDaid H., Church S., Johnston P.G., Cairns M.T. Differential expression of the RIα subunit of protein kinase A (PKA) in a panel of ovarian cell lines and tumours. analysis using RT-PCR Proc. Am. Assoc. Cancer Res. 37:1996;516.
48. McKay R.A., Cummins L.L., Graham M.J., Lesnick E.A., Owens S.R., Winniman M., Dean N.M. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res. 24:1996;411-417.
49. McKnight G.S., Clegg C.H., Uhler M.D., Chrivia J.C., Cadd G.G., Correll L.A., Otten A.D. Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches. Recent Prog. Horm. Res. 44:1988;307-355.
50. Metelev V., Lisziewicz J., Agrawal S. Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg. Med. Chem. Lett. 4:1994;2929-2934.
51. Miller W.R., Hulme M.J., Cho-Chung Y.S., Elton R.A. Types of cyclic AMP binding proteins in human breast cancers. Eur. J. Cancer. 29A:1993;989-991.
52. Miller W.R., Hulme M.J., McCallum J., Cameron D.A., Dixon J.M., Bartlett J.M.S. Tumour RIα mRNA and response to tamoxifen in patients with breast cancer. Proc. Am. Assoc. Cancer Res. 37:1996;238.
53. Mizuno T., Chou M.-Y., Inouye M. A unique mechanism regulating gene expression. translational inhibition by a complementary RNA transcript (micRNA) Proc. Natl. Acad. Sci. USA. 81:1984;1966-1970.
54. Monia B.P. Disruption of the MAP kinase signaling pathway using antisense oligonucleotide inhibitors targeted to ras and raf kinase. Stein C.A., Krieg A.M. In. Applied Antisense Oligonucleotide Technology:1998;245-261 Wiley-Liss, New York.
55. Monia B.P., Lesnik E.A., Gonzalez C., Lima W.F., Guinosso C.J., Kawasaki A.M., Cook P.D., Freier S.M. Evaluation of 2′-modified oligonucleotides containing 2′ deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
56. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2:1996;668-675. a.
57. Monia B.P., Sasmor H., Johnston J.F., Freier S.M., Lesnik E.A., Muller M., Geiger T., Altmann K.-H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxynucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;15481-15484. b.
58. Nakajima F., Imashuku S., Wilimas J., Champion J.E., Green A.A. Distribution and properties of type I and type II binding proteins in the cyclic adenosine 3′:5′-monophosphate-dependent protein kinase system in Wilms' tumor. Cancer Res. 44:1984;5182-5187.
59. Nesterova M., Cho-Chung Y.S. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nature Med. 1:1995;528-533.
60. Nesterova M., Yokozaki H., McDuffie E., Cho-Chung Y.S. Overexpression of RIIβ regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RIIβ Eur. J. Biochem. 235:1996;486-494.
61. Nesterova M.V., Agrawal S., Cho-Chung Y.S. Regulation of multidrug resistance with protein kinase A RIα antisense. Proc. Am. Assoc. Cancer Res. 39:1998;216.
62. Nishida E., Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 18:1993;128-131.
63. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
64. O'Brian C.A., Kuo J.F. Protein kinase C inhibitors. Kuo J.F. Protein Kinase C. 1994;96-120 Oxford University Press, New York.
65. Paterson B.M., Roberts B.E., Kuff E.L. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. USA. 74:1977;4370-4374.
66. Piroli G., Weisenberg L.S., Grillo C., De Nicola A.F. Subcellular distribution of cyclic adenosine 3′,5′-monophosphate-binding protein and estrogen receptors in control pituitaries and estrogen-induced pituitary tumors. J. Natl. Cancer Inst. 82:1990;596-601.
67. Rapp U.R., Cleveland J.L., Storm S.M. Oncogenes. clinical relevance Neth R., Gallo R., Greaves M.F., Vanka G. Proceedings from Modern Trends in Leukemia VII. Hematology and Blood Transfusion:1987;69-77 Springer-Verlag, Berlin.
68. Reddy E.P., Skalka A.M., Curran T. The Oncogene Handbook. 1988;Elsevier Science, Amsterdam.
69. Russell D.H. Type I cyclic AMP-dependent protein kinase as a positive effector of growth. Adv. Cyclic Nucleotide Res. 9:1978;493-506.
70. Schulte T.W., Blagosklonny M.V., Romanova L., Mushinski J.F., Monia B.P., Johnston J.F., Nguyen P., Trepel J., Neckers L.M. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell. Biol. 16:1996;5839-5845.
71. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Helene C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-ras-mediated cell proliferation and tumorgenicity in nude mice. Proc. Natl. Acad. Sci. USA. 91:1994;10460-10464.
72. Schwartz D.A., Rubin C.S. Identification and differential expression of two forms of regulatory subunits (RII) of cAMP-dependent protein kinase II in Friend erythroleukemic cells. J. Biol. Chem. 260:1985;6296-6303.
73. Shibahara S., Mukai S., Morisawa H., Nakashima H., Kobayashi S., Yamamoto N. Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives. Nucleic Acids Res. 17:1989;239-252.
74. Shimizu K., Nakatsu Y., Sekiguchi M., Hokamura K., Tanaka K., Terada M., Sugimura T. Molecular cloning of an activated human oncogene, homologous to v-raf, from primary stomach cancer. Proc. Natl. Acad. Sci. USA. 82:1985;5641-5645.
75. Showers M.O., Maurer R.A. A cloned bovine cDNA encodes an alternate form of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem. 261:1986;16288-16291.
76. Srivastava R.K., Srivastava A.R., Park Y.G., Agrawal S., Cho-Chung Y.S. Antisense depletion of RIα subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Res. Treat. 49:1998;97-107.
77. Srivastava R.K., Srivastava A.R., Seth P., Agrawal S., Cho-Chung Y.S. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RIα subunit. p53-independent mechanism of action Mol. Cell. Biochem. in press:1999.
78. Tagliaferri P., Katsaros D., Clair T., Neckers L., Robins R.K., Cho-Chung Y.S. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J. Biol. Chem. 263:1988;409-416.
79. Taylor S.S., Bubis J., Toner-Webb J., Saraswat L.D., First E.A., Buechler J.A., Knighton D.R., Sowadski J. cAMP-dependent protein kinase. prototype for a family of enzymes FASEB J. 2:1988;2677-2685.
80. Tortora G., Ciardiello F., Ally S., Clair T., Salomon D.S., Cho-Chung Y.S. Site-selective 8-chloroadenosine 3′,5′-cyclic monophosphate inhibits transformation and transforming growth factor α production in Ki-ras-transformed rat fibroblasts. FEBS Lett. 242:1989;363-367. a.
81. Tortora G., Clair T., Katsaros D., Ally S., Colamonici O., Neckers L.M., Tagliaferri P., Jahnsen T., Robins R.K., Cho-Chung Y.S. Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. Proc. Natl. Acad. Sci. USA. 86:1989;2849-2852. b.
82. Tortora G., Clair T., Cho-Chung Y.S. An antisense oligodeoxynucleotide targeted against the type RIIβ regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. USA. 87:1990;705-708.
83. Tortora G., Yokozaki H., Pepe S., Clair T., Cho-Chung Y.S. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 88:1991;2011-2015.
84. Tortora G., Budillon A., Yokozaki H., Clair T., Pepe S., Merlo G., Rohlff C., Cho-Chung Y.S. Retroviral vector-mediated overexpression of the RIIβ subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts. Cell Growth Differ. 5:1994;753-759.
85. Tortora G., Caputo R., Damiano V., Bianco R., Pepe S., Bianco A.R., Jiang Z., Agrawal S., Ciardiello F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA. 94:1997;12586-12591.
86. Uhlenbeck O.C. Complementary oligonucleotide binding to transfer RNA. J. Mol. Biol. 65:1972;25-41.
87. Wakita T., Wands J.R. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J. Biol. Chem. 269:1994;14205-14210.
88. Watson D.M., Hawkins R.A., Bundred N.J., Stewart H.J., Miller W.R. Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br. J. Cancer. 56:1987;141-142.
89. Weber W., Schwoch G., Schröder H., Hilz H. Analysis of cAMP-dependent protein kinases by immunotitration. multiple forms - multiple functions? Cold Spring Harbor Conf. Cell Prolif. 8:1981;125-140.
90. Wehner J.M., Malkinson A.M., Wiser M.F., Sheppard J.R. Cyclic AMP-dependent protein kinases from Balb 3T3 cells and other 3T3 derived lines. J. Cell. Physiol. 108:1981;175-184.
91. Wickstrom E. Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS. 1991;Wiley-Liss, New York.
92. Yasui W., Tahara E. Effect of gastrin on gastric mucosal cyclic adenosine 3′:5′-monophosphate-dependent protein kinase activity in rat stomach carcinogenesis induced by N′-methyl-N-nitrosoguanidine. Cancer Res. 45:1985;4763-4767.
93. Yazaki T., Ahmad S., Chahlavi A., Zylber-Katz E., Dean N.M., Rabkin S.D., Martuza R.L., Glazer R.I. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-α phosphorothioate oligodeoxynucleotide. Mol. Pharmacol. 50:1996;236-242.
94. Yokozaki H., Budillon A., Clair T., Kelley K., Cowan K.H., Rohlff C., Glazer R.I., Cho-Chung Y.S. 8-Chloroadenosine 3′,5′-monophosphate as a novel modulator of multidrug resistance. Int. J. Oncol. 3:1993;423-430. a.
95. Yokozaki H., Budillon A., Tortora G., Meissner S., Beaucage S.L., Miki K., Cho-Chung Y.S. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 53:1993;868-872. b.
96. Young S., Parker P.J., Ullrich A., Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochem. J. 244:1987;775-779.
97. Yuspa S.H. The pathogenesis of squamous cell cancer. lessons learned from studies of skin carcinogenesis. Thirty-third G. H. A. Clowes Memorial Award Lecture Cancer Res. 54:1994;1178-1189.